Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Intravenous ferric carboxymaltose accelerates erythropoietic recovery from experimental malarial anemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.
OriginalsprogEngelsk
TidsskriftThe Internet Journal of Infectious Diseases
Vol/bind208
Udgave nummer3
Sider (fra-til)479-88
Antal sider10
ISSN1528-8366
DOI
StatusUdgivet - 1 aug. 2013

ID: 39017809